Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VSV-hIFNbeta-NIS with or without Ruxolitinib in Advanced Endometrial Cancer
NCT03120624Phase 1Active, not recruiting
- Sponsor
- Mayo Clinic
- Start
- Sep 2017
- Primary completion
- Aug 2023
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of recombinant vesicular stomatitis virus-expressing human interferon beta + sodium-iodide symporter in endometrial cancer (EC) (2 arms), sponsored by Mayo Clinic. Primary endpoint: Dose-limiting Toxicity at 28 days. Started Sep 2017; status: active, not recruiting.
02
Drugs
recombinant vesicular stomatitis virus-expressing human interferon beta + sodium-iodide symporter
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT03120624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03120624.